8-K: OrthoPediatrics Amends Medtech Concepts Purchase Agreement, Opts for Stock Payments

OrthoPediatrics Corp. will issue unregistered shares of common stock to settle remaining payments for the acquisition of Medtech Concepts, LLC, replacing previously agreed-upon cash installments.

Summary

• OrthoPediatrics Corp. amended its Membership Interest Purchase Agreement with Kevin Unger and DINZE LLC on May 9, 2025.
• The amendment involves substituting unregistered shares of OrthoPediatrics' common stock for the remaining cash payments related to the acquisition of Medtech Concepts, LLC.
• The sellers will receive approximately $3,750,000 in stock, divided into three installments of $1,250,000 each, on or around May 1st of 2025, 2026, and 2027.
• These stock payments replace the previously agreed-upon cash payments for the second, third, and fourth anniversary dates of the acquisition.
• The number of shares issued will be determined by dividing $1,250,000 or $2,500,000 (depending on the installment) by the volume-weighted average price of OrthoPediatrics stock over the 30 trading days ending two business days before the applicable anniversary date.
• If OrthoPediatrics stock is no longer listed on Nasdaq or another national securities exchange, the payments will revert to cash.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The company is managing its cash flow by using stock for payments, which could be seen as a positive. However, the dilution of shares is a potential negative.

Positives

• The amendment allows OrthoPediatrics to conserve cash by using its stock for the remaining payments.
• The sellers receive equity in OrthoPediatrics, potentially aligning their interests with the company's long-term success.
• The agreement provides a mechanism for determining the number of shares issued based on the stock's market price.

Negatives

• The issuance of unregistered shares could dilute existing shareholders' equity.
• The sellers may face restrictions on selling the unregistered shares.
• If OrthoPediatrics' stock price declines significantly, the value of the stock payments could be lower than the originally agreed-upon cash payments.

Risks

• The value of the stock issued to the sellers could fluctuate, impacting the overall cost of the acquisition.
• The issuance of new shares could dilute existing shareholders' ownership.
• If OrthoPediatrics' stock is delisted, the company will be required to make the remaining payments in cash, potentially straining its financial resources.

Future Outlook

The company will issue unregistered shares of common stock in lieu of cash payments over the next three years to settle the remaining obligations from the Medtech Concepts acquisition.

Industry Context

This type of amendment, substituting stock for cash in an acquisition agreement, is not uncommon, especially for companies looking to manage their cash flow or align the interests of the acquired company's management with the parent company's long-term performance.

Comparison to Industry Standards

• Many companies in the medical device industry use a combination of cash and stock in acquisition deals.
• The specific mix depends on factors such as the size of the deal, the financial condition of the acquirer, and the preferences of the seller.
• For example, larger companies like Medtronic or Johnson & Johnson often have the resources to pay primarily in cash, while smaller companies may rely more on stock to complete acquisitions.
• The use of unregistered stock is also common, but it typically comes with restrictions on resale to protect existing shareholders.

Stakeholder Impact

• Shareholders may experience dilution due to the issuance of new shares.
• The sellers of Medtech Concepts will become shareholders of OrthoPediatrics.
• The company's cash position may be improved by using stock instead of cash for the payments.

Next Steps

• OrthoPediatrics will issue the first installment of unregistered shares on or around May 1, 2025.
• The company will calculate the number of shares to be issued based on the volume-weighted average price of its stock.
• The sellers will receive the remaining two installments of stock in 2026 and 2027, contingent on Unger's continuous service.

Key Dates

Keywords

OrthoPediatrics, Medtech Concepts, acquisition, stock issuance, amendment, purchase agreement, equity, cash payments